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Abstract
Idiopathic pulmonary fibrosis (IPF) is a complex disease in which a multitude of proteins and networks are disrupted.
Interrogation of the transcriptome through RNA sequencing (RNA-Seq) enables the determination of genes whose
differential expression is most significant in IPF, as well as the detection of alternative splicing events which are not easily
observed with traditional microarray experiments. We sequenced messenger RNA from 8 IPF lung samples and 7 healthy
controls on an Illumina HiSeq 2000, and found evidence for substantial differential gene expression and differential splicing.
873 genes were differentially expressed in IPF (FDR,5%), and 440 unique genes had significant differential splicing events
in at least one exonic region (FDR,5%). We used qPCR to validate the differential exon usage in the second and third most
significant exonic regions, in the genes COL6A3 (RNA-Seq adjusted pval = 7.18e-10) and POSTN (RNA-Seq adjusted
pval = 2.06e-09), which encode the extracellular matrix proteins collagen alpha-3(VI) and periostin. The increased gene-level
expression of periostin has been associated with IPF and its clinical progression, but its differential splicing has not been
studied in the context of this disease. Our results suggest that alternative splicing of these and other genes may be involved
in the pathogenesis of IPF. We have developed an interactive web application which allows users to explore the results of
our RNA-Seq experiment, as well as those of two previously published microarray experiments, and we hope that this will
serve as a resource for future investigations of gene regulation in IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive disease of
unknown aetiology, characterized by fibrotic scarring in the lungs
which leads to shortness of breath and eventual respiratory failure.
The disease typically presents in patients 50–70 years old, with
prevalence increasing with age, and has been shown to have both
genetic and environmental predisposing factors [1], [2]. Median
survival time after diagnosis is only 4–5 years [3], and there is
currently no effective treatment for IPF except lung transplanta-
tion [4].
Current theory of pathogenesis in IPF holds that chronic injury
to alveolar epithelial cells induces aberrant activation of wound-
healing pathways, leading to an increase in inflammatory signals
and subsequent differentiation of fibroblasts, epilthelial-mesenchy-
mal transition in alveolar cells, and accumulation of myofibro-
blasts. This results in the formation of fibroblastic foci and
deposition of collagen, fibronectin, and other extracellular matrix
(EM) components. In contrast with normal wound-healing and for
unknown reasons, apoptosis is not properly initiated in myofibro-
blasts, and secretion of EM proteins does not terminate. This
results in contraction and ultimately destruction of the lung
parenchyma [3], [4].
The primary cause of alveolar injury and dysregulated repair is
still poorly understood, but recent genome-wide association studies
have implicated abnormalities in mucosal defense, cell-cell
adhesion and DNA repair in the development of IPF [5]. Previous
studies have indicated that many other pathways are perturbed in
IPF as well, including TGF-b and WNT signaling and others
related to coagulation, angiogenesis, oxidative stress, and devel-
opment [4]. Genes associated with these pathways have been
found to have differential expression in IPF cases as compared to
healthy controls; however, no effective treatment has yet been
developed which targets any individual gene.
The ability to interrogate mRNA transcripts through RNA
sequencing allows us to find genes whose differential expression
reaches genome-wide significance, and to investigate differential
splicing events on a broad scale. Furthermore this transcriptome-
wide information can be used to inform the study of pathways and
networks which may be dysregulated in IPF. We performed RNA
sequencing on whole lung tissue samples obtained from 8 patients
with IPF and 7 healthy controls in order to investigate these
phenomena and their potential role in the pathogenesis of this
complex disease.
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In addition, a large number of microarray-based gene
expression studies of IPF have been published and the data are
publicly accessible, but there is currently no easy way to visualize
differential expression results across various studies. We further
wanted to make splicing visualizations from our study easily
available and searchable. With this in mind, we have developed an
internet application which allows users to view the results of our
RNA-Seq study interactively, and to compare them with results of
previously published microarray studies: The IPF Gene Explorer,
available from the project website link at http://montgomerylab.
stanford.edu/resources.html. We hope that this application will
make gene expression results more accessible to researchers and
will be a valuable tool in future investigations.
Results
Differential Gene Expression
In comparing the healthy (n = 7) and diseased (n= 8) lung
samples, the Bioconductor package DESeq [6] produced a list of
873 genes showing significant differential expression (DE) at an
FDR of 5%, where sex and demographic group were included as
covariates. These genes had fold changes in the range
0:573vD log2 (fold change)Dv6:894
with one gene (LGALS7) having no counts in the healthy samples.
Overall, we observed more up-regulated genes in the IPF samples
than down-regulated genes (Figure 1). The top ten genes with
smallest p-value are listed in Table 1.
There were 82 unique named genes which showed highly
significant DE (FDR,1%) in both our RNA-Seq data and in two
recent microarray studies [7], [8]. At an FDR of ,1%, our study
identified 475 differentially expressed (DE) genes (8 IPF samples
and 7 controls), whereas microarray experiment GSE24206 (17
IPF, 6 controls) identified 3083 DE genes and microarray
experiment GSE32537 (119 Idiopathic Interstitial Pneumonias,
50 controls) identified 6291 DE genes. The direction of change
found in the RNA-Seq data agrees with that from both microarray
studies for all 82 genes in this overlap. A list of these genes,
together with their p-values and fold changes, may be viewed on
the ‘‘Gene Set’’ page of our web application, by selecting the gene
set ‘‘Microarray overlap’’ and clicking on the ‘‘Table’’ tab.
Figure 1. Differential expression analysis reveals more upregulation than down regulation. This plot depicts fold change vs. mean
expression. Points depict genes, with red indicating those genes that show significant differential expression (FDR,5%).
doi:10.1371/journal.pone.0092111.g001
Table 1. Top ten differentially expressed genes (by p-value).
gene pval padj log2FC description
COMP 4.17e-20 1.28e-15 3.46 cartilage oligomeric matrix protein
DIO2 1.35e-18 2.08e-14 2.75 deiodinase, iodothyronine, type II
CXCL14 1.19e-15 1.22e-11 4.11 chemokine (C-X-C motif) ligand 14
IGLC3 6.04e-15 4.65e-11 4.14 immunoglobulin lambda constant 3 (Kern-Oz+ marker)
PDGFD 1.18e-14 7.29e-11 2.51 platelet derived growth factor D
MMP13 4.11e-14 2.11e-10 3.52 matrix metallopeptidase 13 (collagenase 3)
CDH3 6.83e-14 3.01e-10 2.00 cadherin 3, type 1, P-cadherin (placental)
RP11-731F5.2 3.17e-13 1.22e-09 4.36 lincRNA
IGHG2 4.96e-13 1.70e-09 4.21 immunoglobulin heavy constant gamma 2 (G2m marker)
IGHGP 1.26e-12 3.87e-09 4.41 immunoglobulin heavy constant gamma P (non-functional)
doi:10.1371/journal.pone.0092111.t001
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GWAS Genes are Enriched for Differential Expression
198 SNPs were retrieved from the discovery set of a recent
GWAS study [5] of idiopathic interstitial pneumonia (IIP), a class
of diseases which includes IPF and similar fibrotic diseases of the
lung. The discovery SNPs were those having GWAS pvalue ,
0.0001. We identified 111 genes which were associated with these
SNPs via biomaRt [9] and for which we had sufficient read depth
to test for DE in our RNA-Seq data; of these genes, 8 showed
significant differential expression at an FDR of 5% and are listed
in Table 2. We calculated a hypergeometric p-value of 0.0132 for
the likelihood of seeing 8 significant hits in a gene set of this size
(see Methods), indicating that it is unlikely to see this many genes
showing differential expression by chance alone. Because questions
have been raised about the validity of the hypergeometric (or
Fisher’s exact) test in this context [10], we also calculated an
empirical p-value of 0.01 by a sample permutation method.
The definition of significant differential expression above relies
on an arbitrary FDR cutoff, but we similarly found enrichment for
differential expression using FDR cutoffs of 1% (p-value = 0.093)
and 10% (p-value = 0.040). An alternative view is given by the
QQ-plot in Figure 2, which depicts the quantiles of 2log10 p-
values for the 111 GWAS-identified genes versus the means of
quantiles of 2log10 p-values across 10,000 random gene sets, with
error bars depicting one standard deviation from the mean. This
plot suggests that the GWAS genes are enriched for more
significant DE p-values, even among those that do not pass our 5%
FDR cutoff for significance.
For the 45 SNPs identified as being significantly associated with
IIP in the meta-analysis of [5], 25 corresponded to genes we tested
in DESeq with 2 being significant, giving a hypergeometric p-
value of 0.158. Although this p-value is not as low as the p-value
for the discovery set of GWAS SNPs, the QQ-plots in Figure 3 and
Figure 4 show that the distribution of p-values in validated GWAS
SNPs has a larger deviation from the diagonal, indicating that
these higher confidence GWAS SNPs may still have a greater
enrichment for DE genes than the discovery set.
The most striking observation about the genes in Table 2 is that
all have been implicated in cellular adhesion, migration, or
invasion, underscoring the observation made in [5] that cell-cell
Table 2. Genes associated with GWAS [5] validation SNPs which are differentially expressed in RNA-Seq data at 5% FDR.
gene pval padj log2FC description GWAS significant rsids
RNF5 9.46e-07 2.04e-04 22.16 ring finger protein 5, E3 ubiquitin protein ligase rs3134943
MUC5B 6.50e-06 9.05e-04 4.63 mucin 5B, oligomeric mucus/gel-forming rs12417955, rs2735727, rs2857476, rs868903
DSP 8.83e-05 6.40e-03 1.16 desmoplakin rs10484325, rs10484326, rs2076295,
rs2076302, rs3778337
AGER 1.03e-04 7.27e-03 22.28 advanced glycosylation end product-specific receptor rs3134943
SRGAP3 2.45e-04 1.41e-02 1.31 SLIT-ROBO Rho GTPase activating protein 3 rs12638703
MAPK10 7.46e-04 3.23e-02 0.76 mitogen-activated protein kinase 10 rs4488910
FAT1 9.27e-04 3.71e-02 0.93 FAT atypical cadherin 1 rs2130910
HBEGF 1.33e-03 4.76e-02 21.05 heparin-binding EGF-like growth factor rs13385
The two genes in bold have corresponding SNPs which were validated by the GWAS meta-analysis.
doi:10.1371/journal.pone.0092111.t002
Figure 2. GWAS genes identified from discovery SNPs appear
to be enriched for differential expression. X-axis values of dots
indicate the mean 2log10(pval) from 10,000 randomly permuted sets,
and error bars indicate one standard deviation from the mean in these
permutations.
doi:10.1371/journal.pone.0092111.g002
Figure 3. GWAS genes identified from validated SNPs appear
to be enriched for differential expression. X-axis values of dots
indicate the mean 2log10(pval) from 10,000 randomly permuted sets,
and error bars indicate one standard deviation from the mean in these
permutations.
doi:10.1371/journal.pone.0092111.g003
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adhesion should be high on the list of processes considered for
further research and potential therapeutic interventions.
Our results confirm those of [5] showing that MUC5B and DSP
are significantly over-expressed in IPF lungs as compared to
controls, and these genes are discussed in detail in this previous
study; in particular DSP is involved in cell adhesion via the
connection of cytoskeleton to cell membrane.
RNF5 is an E3 ubiquitin ligase which has been associated with
focal adhesion as well as endoplasmic reticulum stress response
[11], and is proposed to be a regulator of breast cancer progression
through its effects on actin cytoskeleta [12]. RNF5 acts by
ubiquitination of the protein paxillin, decreasing its localization in
focal adhesions and impairing cell motility [13].
AGER encodes a receptor for advanced glycosylation end-
product which is normally highly expressed in adult lung, and
which has been shown to be significantly down-regulated in IPF
lungs as compared to controls [14], [15]. A decrease in this gene’s
protein product (RAGE) has been shown to impede cellular
adhesion to collagen, leading to increased migration of epithelial
cells and fibroblasts [15]. RAGE is also associated with the
differentiation of alveolar epithelial type II cells into alveolar type I
cells [16].
SRGAP3 (MEGAP) is a small GTPase involved in the Slit-Robo
pathway which plays a role in neuronal development and has been
implicated in X-specific mental retardation [17]. In this context it
has been shown that SRGAP3 inhibits the formation of focal
complexes and alters the actin and microtubule cytoskeleton,
thereby impeding cell migration [18].
MAPK10 is the gene encoding the enzyme mitogen-activated
protein kinase 10, also known as JNK3. The related kinase JNK1
contributes to TGFb1-induced epithelial to mesenchymal transi-
tion and collagen deposition, and has been shown to be necessary
for the development of pulmonary fibrosis in a mouse model [19];
however contrary to our findings, this study reports that JNK3
expression is limited to heart, testis, and brain. JNK has been
shown to be activated in IPF tissues [20], where it appears to play
a role in persistence of myofibroblasts [21], and inhibition of JNK
has been shown to enhance cell-cell adhesion [22].
FAT1 encodes a protein that belongs to the cadherin
superfamily of membrane proteins. Previous research has shown
that FAT1 is involved with actin dynamics and cellular
polarization in mammalian (rat/mouse) cell lines; in particular it
was shown to be necessary for regulation of cellular motility in
wound closing, in that a knockdown of this protein led to a
decrease in cell migration [23]. FAT1 has also been associated
with liver fibrosis [24].
Heparin-binding EGF-like growth factor (HBEGF) is an
epidermal growth factor which affects multiple cell types, including
fibroblasts, keratinocytes, and vascular smooth muscle cells, and
has been associated in various ways with fibrosis occuring in the
heart, liver, and pancreas of mice or rats [25], [26], [27]. It
promotes the survival and proliferation of mesenchymal cells like
fibroblasts and myofibroblasts, which is a key element in the
progression of a normal response to lung injury to a pathologic
state of fibrosis [28]. HBEGF has been shown to enhance cellular
adhesion to the extracellular matrix, as well as invasion,
angiogenesis and EMT in the context of ovarian cancer [29]. It
has also been shown to increase migration in keratinocytes [30]
and human peritoneal membrane cells [31].
Network Analysis
The results of our network analysis recapitulate those described
in other studies, underscoring that IPF is a disease in which many
pathways are disrupted. Tables 3, 4, and 5 list those pathways
identified by SPIA [32] as being significantly perturbed at an FDR
of ,10%, where we provided SPIA with a list of genes found to be
significantly differentially expressed in our RNA-Seq data at FDRs
of 1%, 5% and 10%, respectively.
We also performed a gene-set enrichment analysis (see Methods)
on the results of the differential expression analyses for our RNA-
Seq data, first for gene-level expression and then for differential
exon usage. Five pathways showed up as being significant at FDR
10% in both analyses; these are listed in Table 6.
Alternative Splicing
The Bioconductor package DEXSeq [33] discovered 675
differentially expressed exonic regions (FDR,5%), which lie in
436 unique named genes. The top ten significant regions are listed
in Table 7. We were unable to perform PCR validation for the first
Figure 4. GWAS identified genes appear to be enriched for
differential expression. We see smaller differential expression p-
values for GWAS genes than for randomly selected genes.
doi:10.1371/journal.pone.0092111.g004
Table 3. SPIA results when provided with DE genes significant at 1% FDR.
Name FDR Status
Salivary secretion 0.0329 Inhibited
Pancreatic secretion 0.0441 Inhibited
ECM-receptor interaction 0.0441 Activated
Focal adhesion 0.0785 Activated
doi:10.1371/journal.pone.0092111.t003
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exonic hit, RPS24, because the GC-content of the region
prevented us from designing a high-quality primer within the
differentially expressed exon. However we did validate differential
usage in the second and third most significant regions, within the
genes POSTN and COL6A3, by using a second exon in each
respective gene as a control and proxy for gene-level expression.
PCR confirmed that usage of these exons was depressed in IPF as
compared to controls, with both exons giving a Wilcoxon rank-
sum p-value of 3.108e-4, the smallest p-value possible in this
nonparametric rank-based test.
POSTN. The third most significant result lies in the gene
encoding periostin (POSTN). Figure 5 shows that exon 21,
labelled as bin E013 in the figure, is more likely to be spliced out in
IPF samples than in controls; shown are the fitted expression and
fitted splicing coefficients, for which E013 is relatively lower in IPF
than other exonic regions in the gene (see [33] for more on fitted
coefficients). To perform real-time PCR validation, we designed
primers to amplify exon 21 as well as exon 20, an adjacent exon
that is present in all annotated transcripts of POSTN. For this
reason, the expression of exon 20 was used as an internal baseline
from which to estimate the proportion of POSTN transcripts
lacking exon 21.
The ratios calculated for the expression of exon 21 versus exon
20 by PCR are in good linear agreement with the ratios calculated
from normalized counts in the RNA-Seq data: a linear regression
with intercept 0 has adjusted R2 = 0.946, F=261.9 with p-value
1.86e-10 (Figure 6). In addition the PCR data validates the finding
that these ratios are smaller in IPF samples than in healthy
controls (Wilcoxon rank-sum p-value = 3.108e-4, Figure 7).
POSTN encodes the secreted extracellular matrix protein
periostin, whose increased expression has previously been associ-
ated with IPF [34], and whose expression levels have been
reported to be predictive of clinical progression in IPF [35]. Other
studies have implicated periostin in murine models of lung fibrosis,
where it has been shown to induce chemokines to recruit
neutrophils and macrophages [36]. Like the proteins associated
with GWAS SNPs in the previous section, periostin is involved in
cell adhesion and migration. It has been implicated in tumor
invasion via a contribution to epithelieal-mesenchymal transition
[37], [38], and it enhances TGF-b-induced myofibroblast
differentiation in neonatal lungs [39].
Although our RNA-Seq data does indicate that gene-level
expression of POSTN is increased in IPF samples by a factor of 2,
this increase did not reach genome-wide significance in our study
(p-value = 9.5e-3), adjusted p-value = 0.1685), whereas relative
down-regulation of exon 21 was highly significant (p-va-
lue = 3.01e-14, adjusted p-value = 2.06e-9).
Full length periostin consists of 23 exons and there are nine
reported isoforms [40]; some of these isoforms were detected only
in fetal lung or renal tissue and not in adult lungs. The N-terminal
region of the protein is conserved. Isoforms vary in the cassette
exons 17–21 of the C-terminal region, and it has been proposed
that this region binds ECM proteins like collagen and fibronectin,
so that differences in the constitutive exons of this region should
affect interactions with the ECM [41]. Indeed it has been shown
that periostin isoforms have differential effects on cell invasiveness
in several models [42].
Table 4. SPIA results when provided with DE genes significant at 5% FDR.
Name FDR Status
Salivary secretion 0.0007 Inhibited
TGF-beta signaling pathway 0.0022 Activated
Amoebiasis 0.0483 Inhibited
ECM-receptor interaction 0.0483 Activated
Basal cell carcinoma 0.0643 Inhibited
Wnt signaling pathway 0.0866 Inhibited
doi:10.1371/journal.pone.0092111.t004
Table 5. SPIA results when provided with DE genes significant at 10% FDR.
Name FDR Status
Amoebiasis 0.0008 Inhibited
Salivary secretion 0.0008 Inhibited
TGF-beta signaling pathway 0.0035 Activated
Complement and coagulation cascades 0.0254 Inhibited
ECM-receptor interaction 0.0523 Activated
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.0523 Activated
Pathways in cancer 0.0523 Inhibited
Dilated cardiomyopathy 0.0676 Activated
Wnt signaling pathway 0.0729 Inhibited
Transcriptional misregulation in cancer 0.0729 Inhibited
Basal cell carcinoma 0.0729 Inhibited
doi:10.1371/journal.pone.0092111.t005
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COL6A3. The second most significant result lies in exon 4 of
the gene COL6A3, and is more likely to be spliced out in IPF
samples than in controls. A probe within exon 9 of COL6A3,
which did not show differential splicing in the RNA-Seq data or
evidence of SNPs within our samples, was chosen as an internal
reference. Ratios calculated for the expression of exon 4 to exon 9
by PCR agree linearly with those calculated by RNA-Seq, giving
adjusted R2 = 0.803 and F=62.24 with p-value 1.61e-6, calculated
as for POSTN (Figure 8). Furthermore the PCR data validates
that these ratios are smaller in IPF samples than in healthy
controls (Wilcoxon rank-sum p-value = 3.108e-4), as shown in
Figure 9).
COL6A3 does not show differential gene-level expression in our
RNA-Seq data, but it is significantly upregulated in IPF in the two
previously published microarray experiments described above
(GSE24206 padj = 3.16e-02, GSE32537 padj = 8.26e-17). Like
periostin, collagen VI is an extracellular matrix protein which is
involved in cellular adhesion [43]; it is also associated with integrin
signaling. Differential splicing of COL6A3, and in particular of
exon 4, has previously been associated with pancreatic cancer [44]
and colon cancer [45], though in these studies it was inclusion as
opposed to exclusion of exon 4 that associated with the disease
phenotype. COL6A3 has been shown to be a target of the TGF-
b/Smad signaling pathway [46], which is believed to play a role in
the pathogenesis of idiopathic pulmonary fibrosis [4].
IPF Gene Explorer
We created a web application built from the shiny package for
R [47] to visualize the results of our gene expression study as well
as previously published microarray studies. The website consists of
two pages: one dedicated to viewing information about a single
gene (Figure 10), and another for visualizing sets of genes
(Figure 11), such as genes involved in a biological pathway or
genes which are significantly differentially expressed.
The single gene page takes as input a gene by its HGNC gene
symbol, and displays the p-values, adjusted p-values, and fold
changes found in our study and in two recent microarray
experiments [7], [8]. Boxplots of expression data are shown; for
RNA-Seq data the user may choose to see counts, log-normalized
counts, or variance stabilized expression data [6]. For the
microarray experiments, expression data has been processed as
described in the respective papers: briefly, log transformed data is
normalized by Robust Multi-array Average (RMA), and in the
case of GSE32537, expression values for probes in the same gene
are averaged and a variance filter is employed [7], [8].
The gene set page provides a number of ways for visualizing the
relative expression of genes across our 15 samples, including an
interactive barchart, an expression plot, and a heatmap. The user
may also view and download a table showing p-values, adjusted p-
values, and log fold changes for the genes in the set.
Discussion
Interrogation of transcription through RNA sequencing enabled
us to discover genes whose differential expression reaches genome-
wide significance in IPF, and to detect alternative splicing events
which are not easily observed with traditional microarray
experiments. We identified many differentially expressed genes
and exonic regions, and validated two alternative splicing events
by quantitative PCR. We believe these results indicate a potential
role for alternative splicing of periostin and collagen VI alpha-3 in
IPF, but more investigation is needed to determine the cell types in
which alternative splicing is operative, and to identify causal
Table 6. Pathways enriched for differentially expressed genes and for differentially spliced genes in the RNA-Seq data.
pathway DE padj DEX padj
KEGG: ECM-receptor interaction ,0.00275 0.010267
Reactome: Steroid metabolism ,0.00275 0.076444
Reactome: Integrin cell-surface interactions 0.018419 0.083849
Reactome: Signaling by VEGF 0.069841 0.023158
Reactome: Hemostasis 0.095437 0.017600
doi:10.1371/journal.pone.0092111.t006
Table 7. Top ten differentially expressed exons (by p-value).
gene pval padj exon description in IPF
RPS24 1.67e-15 3.42e-10 chr10:79800373–79800428 ribosomal protein S24 down-regulated
COL6A3 6.99e-15 7.18e-10 chr2:238296225–238296720 collagen, type VI, alpha 3 down-regulated
POSTN 3.01e-14 2.06e-09 chr13:38143437–38143520 periostin, osteoblast specific factor down-regulated
DLC1 5.82e-12 2.99e-07 chr8:13356583–13357330 deleted in liver cancer 1 up-regulated
COL3A1 4.03e-11 1.66e-06 chr2:189867756–189867788 collagen, type III, alpha 1 down-regulated
ZFP36L1 4.97e-11 1.70e-06 chr14:69261464–69262759 ZFP36 ring finger protein-like 1 down-regulated
COL3A1 5.84e-10 1.66e-05 chr2:189868460–189868513 collagen, type III, alpha 1 down-regulated
GM2A 6.46e-10 1.66e-05 chr5:150646857–150650001 GM2 ganglioside activator up-regulated
COL3A1 9.89e-10 2.26e-05 chr2:189868149–189868190 collagen, type III, alpha 1 down-regulated
TRA2B 1.75e-09 3.30e-05 chr3:185652294–185654025 transformer 2 beta homolog (Drosophila) down-regulated
doi:10.1371/journal.pone.0092111.t007
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variants and mechanisms of this effect and their relationship to
IPF. We were not able to reproduce POSTN splicing results in a
smaller sample of IPF lung fibroblasts (4 IPF samples and 4 healthy
controls); this could indicate that the effect manifests primarily in a
different cell type, or that we had insufficient power to detect the
effect with this small sample size. We looked at SNPs from the
1000 Genomes CEU population (Utah residents with Northern
European ancestry) lying within 50bp of periostin and COL6A3
splice sites, and found that none of these variants were significantly
associated with IPF in the recent GWAS study [5]. Our results
indicate that RNA-Seq has the potential to identify novel gene
targets for further research, and larger studies and follow-up
experiments will shed further light on the mechanisms underlying
IPF. We believe that public access and easy visualization of results
will enhance research efforts across disciplines in understanding
this disease.
To our knowledge there has been only one published study
examining gene expression in IPF lung tissues via RNA-Seq [48],
which used samples from three IPF lungs and three COPD
controls. Although this previous study did find differential splicing
of periostin at an FDR of ,10% (adjusted p-value = 0.0694),
overall the set of genes which they find to have significant
differential splicing at FDR ,5% has small overlap with the set of
genes having at least one differentially expressed exonic region
(FDR,5%) in our data: only 7 genes are claimed to be
significantly differentially spliced in both experiments, which is
not more than expected by chance alone (1628 genes tested by
both experiments, of which 147 are called significant here and 132
are called significant in [48]). There could be many reasons for this
lack of replication. First, control samples are drawn from different
clinical groups; second, [48] uses transcript quantification where
we use differential exon usage, which introduces an extra layer of
statistical modelling and estimation; third, both study sizes are
relatively small, though our larger sample size should give us
greater power to detect effects.
Materials and Methods
Unprocessed fastq files and processed gene and exon counts are
available at NCBI’s Sequence Read Archive (SRA) and NCBI’s
Gene Expression Omnibus [49] through the GEO Series accession
number GSE52463 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc =GSE52463). Scripts for downstream quantitative
analyses are available at https://github.com/datapixie/ipf.
Figure 5. Periostin (POSTN) shows evidence of differential splicing at exon 21. In this splicing plot produced by DEXSeq, exon 21 (labelled
E013) is highlighted in magenta.
doi:10.1371/journal.pone.0092111.g005
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IRB Protocols
Sample collection and research activities approved by Univer-
sity of Pittsburgh IRB protocol: IRB970946 and by Stanford IRB
protocol: 18891 (Pathogenesis and progression of interstitial lung
disease). Participants provided written consent to participate in
study. The ethics committees approved the consent procedure. All
data was analyzed anonymously.
Human Lung Samples
We obtained 8 healthy lung samples and 8 IPF lung samples
from resources within Stanford University and the University of
Pittsburgh. IPF tissue was obtained from patients undergoing
surgical biopsy or transplantation for the diagnosis of interstitial
lung disease or lung transplant for IPF. Control lung tissue was
taken from patients undergoing lung cancer resection, remote
from the cancer, or from donor explant lung which was not
deemed suitable for transplantation. These samples were taken
from heart-beating patients without prior flushing of the lungs.
One healthy sample was determined to have extreme-outlier
patterns of gene expression relative to the other 15 lung samples,
and was excluded from downstream analyses (Figure 12). In
particular, it showed extremely low expression of lung surfactant
proteins SFTPA, SFTPC, and SFTPB (Table 8).
Genotyping and Determination of Covariates
All samples were genotyped on Illumina Human Exome
BeadChips, which give allelic information at .200,000 SNPs.
Principal components (PC) analysis [50] was performed on these
genotypes, with the first two PCs revealing three distinct clusters
(Figure 13). Comparison to data from the Phase-One Thousand
Genomes project [51] showed that this clustering corresponded to
demographic structure among samples (Figure 14). We identified
two IPF samples as coming from individuals of Asian descent and
three samples from admixed or American descent, while the rest
cluster with samples of European descent. The inclusion of each
sample into one of these three demographic groups was used as a
covariate in downstream differential expression analyses. We used
Plink’s sex check tool (based on heterozygosity rates on the X
chromosome [52]) to identify the sex of each sample, which was
also used as a covariate.
Figure 6. Ratios of periostin exon usage calculated from qPCR
vs. RNA-Seq. The grey area indicates 95% confidence interval for the
linear regression.
doi:10.1371/journal.pone.0092111.g006
Figure 7. qPCR confirms down-regulation of POSTN exon 21 in
IPF lung tissue. Shown are PCR ratios of POSTN exon usage for IPF vs
controls (Wilcoxon p-value= 3.108e-4).
doi:10.1371/journal.pone.0092111.g007
Figure 8. Ratios of COL6A3 exon usage calculated from qPCR vs.
RNA-Seq. The grey area indicates 95% confidence interval for the linear
regression.
doi:10.1371/journal.pone.0092111.g008
Figure 9. qPCR confirms down-regulation of COL6A3 exon 4 in
IPF lung tissue. Shown are PCR ratios of COL6A3 exon usage for IPF vs
controls (Wilcoxon p-value= 3.108e-4).
doi:10.1371/journal.pone.0092111.g009
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Library Preparation and Sequencing
RNA was isolated from all lung samples with Trizol and rRNA
was depleted using the Ribo-Zero Magnetic Kit (Epicentre,
Madison, WI). Briefly, 1 mg total RNA was incubated with rRNA
removal solution containing rRNA specific probes according to
instructions at 68uC for 10 minutes. rRNA bound to probes was
removed by magnetic bead pull-down. The final ribosomal
depleted RNA was recovered following sodium acetate/glycogen
addition and ethanol precipitation overnight. Samples were
centrifuged at 10,0006g for 30 min, washed once per instruction,
and resuspended with RNAse-free water. The remaining ribo-
somal depleted RNA was used to generate cDNA libraries using
the Illumina TruSeq RNA preparation kit. Strand specificity was
performed using dUTP during second strand synthesis. All
samples were indexed with Illumina adapters and sequenced
using an Illumina HiSeq 2000.
Figure 10. The IPF Gene Explorer displays expression data for a single user-selected gene.
doi:10.1371/journal.pone.0092111.g010
Figure 11. The IPF Gene Set Explorer displays expression data for a set of user-selected genes.
doi:10.1371/journal.pone.0092111.g011
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Alignment and Counting of RNA-Seq Reads
Reads were aligned to the UCSC hg19 human reference
genome using default parameters with STAR v2.0.2c [53], which
was provided with splice junction information from Gencode v.14
annotation. The median number of reads for all 16 samples was
about 26 million, and the median number of uniquely mapped
reads was about 22.5 million (Table 9). Nonuniquely mapped
reads and reads mapping to mitochondrial DNA were discarded.
An in-house script was used to count reads over each gene in the
gencode annotation, and DEXSeq-bundled scripts were used to
count reads lying in non-overlapping exonic parts, as described in
[54]. Read mappings were required to be properly stranded when
performing these counts.
Differential Expression Analysis
The bioconductor package DESeq tests for differential gene
expression by modeling read counts with a negative binomial
distribution, where means are predicted via a generalized linear
model (GLM) with logarithmic link and dependencies of variance
on mean are estimated from the data. DESeq tests for differential
expression by comparing the fit of the GLM with disease-state
coefficient to one without, via a x2 likelihood-ratio test [6]. After
filtering out the 40% lowest-expressed genes (Figure 15), we used
DESeq v.1.10.1 to identify genes that were differentially expressed
between IPF samples and healthy controls. The ‘‘pooled-CR’’
option was used to estimate dispersions and resulting p-values were
adjusted by the method of Benjamini-Hochberg (BH) to account
for multiple testing [55]. The related package DEXSeq v.1.0.2
[33] was used to find differential exon usage between the two
cohorts. Overlapping genes were excluded from the differential
exon analysis. Demographic group and sex were added as
covariates in the generalized linear models used by both DESeq
and DEXSeq.
Microarray Comparison
We compared differentially expressed genes found in the RNA-
Seq data with two recently published studies which used
microarrays to estimate relative transcript expression [7], [8].
The data for these studies are publicly available on the Gene
Expression Omnibus (GEO) website (accession IDs GSE24206
and GSE32537) [49]. Differential expression analysis was
performed using the limma package [56], [57], via R scripts
produced by GEO’s geo2R application.
Gene Network Analysis
We determined pathway enrichment for differentially expressed
or spliced genes by a method using p-value enrichment
permutation analysis [58]. Gene sets were obtained from the
following online databases: BioCarta (www.biocarta.com), KEGG
(www.genome.jp/kegg), Pathway Interaction Database (pid.nci.-
nih.gov), Reactome (www.reactome.org), SigmaAldrich (www.
sigmaaldrich.com/life-science.html), Signaling Gateway (www.
signaling-gateway.org), Signal Transduction KE (stke.sciencema-
g.org), SuperArray (www.superarray.com). A score for each gene
(resp., exon) was computed as the negative log10 of the p-value
output from DESeq, and the median of scores in each gene set was
used as the gene set’s score. Gene (exon) scores were permuted so
as to preserve the number of genes (exons) in each pathway and
the number of pathways corresponding to each gene; gene set
scores were then recomputed, and this was repeated 10,000 times.
The distribution of scores for each gene set was used to establish
an empirical p-value, and p-values for gene sets were adjusted by
BH.
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Figure 12. Norm 7 is an outlier in gene expression. This heatmap shows the top 50 most highly expressed genes (average across all samples)
and corresponding hierarchical clustering of samples.
doi:10.1371/journal.pone.0092111.g012
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We compared these results with those from SPIA [32], a
Bioconductor network analysis package which incorporates
knowledge of network topology and gene expression fold change
to determine if a pathway is activated or inactivated in IPF relative
to healthy samples. We provided SPIA with the fold changes of
genes which were found to have significant differential expression
at 1%, 5%, and 10% FDR. Because SPIA utilizes information at
the gene-level, this analysis could not be used to identify pathways
enriched for alternative splicing events.
GWAS Enrichment
In order to determine whether the overlap between the set of
differentially expressed genes and the set of GWAS-identified
genes (both considered as subsets of those genes tested for
differential expression) is larger than expected by chance alone, we
calculated a p-value of 0.013 from the hypergeometric distribution
in R as:
phyper(q~8{1, m~873, n~30762{873,
k~110, lower:tail~FALSE)
where q is the size of the overlap minus one, m is the number of
genes found to be significantly differentially expressed at FDR 5%,
n is the number of ensembl IDs tested for differential expression
which were not called significant, and k is the number of GWAS-
identified genes which were tested for differential expression. This
p-value is equal to the probability of drawing 8 or more green balls
from an urn containing 873 green balls and 29889 red balls, when
you have drawn a total of 110 balls randomly from the urn. Since
the p-value indicates that it is unlikely to see an intersection of 8
genes by chance alone, we conclude that the GWAS-identified
genes are enriched for differential expression. Other hypergeo-
metric p-values were calculated similarly.
Figure 13. Subject genotypes cluster into three demographic groups. The first two principal components of sample genotype scores
separate samples into three clusters.
doi:10.1371/journal.pone.0092111.g013
Figure 14. The three genotype clusters correspond to sample population-of-origin. The first two principal components for sample
genotypes combined with corresponding Thousand Genomes genotypes are shown.
doi:10.1371/journal.pone.0092111.g014
Splicing in IPF Lung
PLOS ONE | www.plosone.org 12 March 2014 | Volume 9 | Issue 3 | e92111
For the sample-based permutation approach, we permuted the
disease status (IPF or healthy) of our 15 subjects. For each
permutation, DESeq was rerun and the size of overlap between
significant genes and GWAS genes was computed. We ran 200
permutations, and of these only two had overlaps of size 8 or
larger, giving an empirical p-value of 0.01.
PCR Validation
POSTN primers for exons 20 and 21 were designed to produce
amplicons of approximately the same length that were solely
contained within each respective exon at final concentrations of
500nM (POSTN 20FWD-2: ACTAGGATTTCTACTGGAGG-
TGGA; POSTN 20REV-2: ACAATTTCTTCAGAGTTTCT-
TCTGT; POSTN 21 FWD-2: AGGTCACCAAGGTCACCA-
AA; POSTN 21REV-3 TCAAATAAATGACCATCACCAC-
CT). Phusion High-Fidelity Polymerase (0.02U/ul) and 1x buffer
(NEB, Ipswich, MA) were used with a final concentration of 0.6x
SYBR Green (Molecular Probes, Eugene OR) and 0.2mM dNTPs
for 40 cycles on a StepOnePlus Real-Time Q-PCR machine (Life
Technologies, Carlsbad, CA). cDNA libraries used for RNA-Seq
representing healthy and IPF lung samples were diluted over 5
Table 9. Numbers of reads sequenced for each sample.
sample number of reads uniquely mapped reads
Norm1 20623466 17354393
Norm2 19711643 16939631
Norm3 23850384 21326596
Norm4 27568156 25210789
Norm5 21328567 18264192
Norm6 26054686 22831687
Norm7 29606940 26957981
Norm8 27182913 23959608
IPF1 21822005 18861962
IPF2 26696309 23524193
IPF3 28104723 24908240
IPF4 26197318 23168922
IPF5 23401239 20251950
IPF6 26780342 22191034
IPF7 23413788 20835580
IPF8 29640467 25248566
doi:10.1371/journal.pone.0092111.t009
Figure 15. Genes with low read count are filtered prior to testing for differential expression. Each point represents a gene. We are able to
increase our detection power by eliminating tests which have read counts below the 40th percentile, and therefore would have small probability of
attaining significance [6].
doi:10.1371/journal.pone.0092111.g015
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two-fold dilutions for Q-PCR and amplified to produce standard
curves.
Real time PCR was performed for each sample and each of the
two primers at five different dilutions. For each sample, the
machine-calculated optimal threshold was found for each exon
primer and concentration separately, and Ct values were calculated
by using the mean of these thresholds for both exons. We then
calculated standard curves for each (sample, exon) pair as a quality
control to confirm linearity between Ct and log concentration. The
expression ratio for each sample was calculated as
expression of exon 21
expression of exon 20
~2Ct(20){Ct(21)
where Ct(j) is the Ct value found for exon j at the most concentrated
dilution (0.1).
PCR validation for COL6A3 was performed similarly (primers
COL6A3 E057-FWD: CCGATATTGGCCAACTCCCC; CO-
L6A3 E057-REV: GACACCTACTCCACCAAGGC; COL6A3
E050-FWD: ATGAGGGTGCGAACGTACTG; COL6A3 E050-
REV: GCAAGAGGGACGTGGTCTTT).
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